Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen cash Flow Statement — Operating cash flow ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows (DB)
Latest, FY2025
9,958
Period ended Dec 31, 2025
Change on a year earlier
-13.3%
11,490 in FY2024
History
19 years
Since FY2007
Sources
15
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash Flow Statement — Operating cash flow ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,958 | -13.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 11,490 | +35.6% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 8,471 | -12.9% | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 9,721 | +5.0% | Form 10-K (filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 9,261 | -11.8% | Form 10-K (filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 10,497 | +14.7% | Form 10-K (filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 9,150 | -19.0% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 11,296 | +1.1% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 11,177 | +7.9% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 10,354 | +6.4% | Form 10-K (filed 2017-02-14) ↗ |
| FY2015 | Dec 31, 2015 | 9,731 | +8.7% | Form 10-K (filed 2017-02-14) ↗ |
| FY2014 | Dec 31, 2014 | 8,952 | +42.3% | Form 10-K (filed 2017-02-14) ↗ |
| FY2013 | Dec 31, 2013 | 6,291 | +7.0% | Form 10-K (filed 2014-02-24) ↗ |
| FY2012 | Dec 31, 2012 | 5,882 | +14.9% | Form 10-K (filed 2013-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 5,119 | -11.5% | Form 10-K (filed 2012-02-29) ↗ |
| FY2010 | Dec 31, 2010 | 5,787 | -8.7% | Form 10-K (filed 2011-02-25) ↗ |
| FY2009 | Dec 31, 2009 | 6,336 | +5.8% | Form 10-K (filed 2010-03-01) ↗ |
| FY2008 | Dec 31, 2008 | 5,988 | +10.9% | Form 10-K (filed 2010-03-01) ↗ |
| FY2007 | Dec 31, 2007 | 5,401 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up cash flow statement — operating cash flow ($m)
- Depreciation and amortization ($M)5,167 · FY2025
- Stock-based compensation ($M)494 · FY2025
- Deferred income taxes ($M)-700 · FY2025
- Change in trade receivables ($M)-2,676 · FY2025
- Change in inventories ($M)886 · FY2025
- Change in accounts payable ($M)428 · FY2025
- Capital expenditures ($M)1,858 · FY2025
- Net cash used in investing activities ($M)-1,943 · FY2025
- Proceeds from issuance of long-term debt ($M)0 · FY2025
- Repayments of long-term debt ($M)5,000 · FY2025
- Cash dividends paid ($M)5,124 · FY2025
- Repurchases of common stock ($M)-0 · FY2025
- Net cash used in financing activities ($M)-10,859 · FY2025
- Cash paid for interest, net ($M)2,900 · FY2025
- Cash paid for income taxes, net ($M)4,300 · FY2025
Cite this data
StockData. (2026). Amgen Cash Flow Statement — Operating cash flow ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_cash_flow
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.